Frequently asked questions
In 2022, the global Hospital Infection Therapeutics Market is expected to be worth USD 10512.5 million.
The Hospital Infection Therapeutics Market is estimated to increase at a CAGR of 5.00% between 2023 and 2030, reaching USD 13111.4 Million in 2030.
Surgical Site Infections (SSIs) lead the hospital therapeutics market in 2022
Retail pharmacies have the highest market demand
Outpatient Clinics have the highest compound annual growth rate (CAGR) in the industry
North America is expected to dominate the market in 2022, accounting for 40% of total revenue.
The top players include Merck & Co., Inc.; Pfizer Inc.; Bayer AG; GlaxoSmithKline Plc.; Daiichi Sankyo Company, Limited; AbbVie Inc.; Abbott Laboratories; F. Hoffmann-La Roche Ltd; and Allergan Plc.
The primary drivers of the market are the increasing frequency of hospital-acquired illnesses, growing awareness of the necessity of infection control measures, and advancements in technology and research.
The market’s main hurdles include the emergence of antibiotic resistance, the high cost of researching and manufacturing novel treatments, stringent regulatory regulations, and limited access to healthcare facilities in some countries.
Novel medicines and treatment techniques are being developed. Infection control solutions are in high demand, and The market potential is collaboration and partnerships between pharmaceutical firms and healthcare providers.